(Q84366865)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Angiotensin II receptor blocker is a renoprotective remedy for metabolic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Tadashi Sofue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Hideyasu Kiyomoto

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

7 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

published in

Hypertension Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

735-737

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/hr.2009.123

4 February 2020

exact match

0 references

cites work

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Regulation of intrarenal angiotensin II in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Glomerular hyperfiltration: a new marker of metabolic risk.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.123

7 January 2021

Identifiers

DOI

10.1038/HR.2009.123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19662021%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference